A Phase II Study Evaluating Efficacy and Safety of Hypomethylating Agent Guadecitabine in Combination with Carboplatin in Extensive Stage Small Cell Lung Cancer
The purpose of this study is to find out if the combination of guadecitabine with carboplatin is better or worse than the usual approach for small cell lung cancer.
- IRB Number: 1902370856 (LUN17-302)
- Research Study Identifier: TX10264
- Principal Investigator: Shadia Jalal, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required